leisure time -WSS

leisure time

author：comprehensive 2025-09-29 01:09:38 - browse：89

European Medicines Agency Suffers Cyber Attack in Amsterdam — Paulo Amorim / VWPics via AP Images

LONDON — European regulators on Friday reiterated their view that an ALS treatment from Amylyx Pharmaceuticals should not be approved, likely dooming the drug’s chances for now.

A European Medicines Agency committee had initially recommended against approving the drug, known as Albrioza, in June. Friday’s confirmation of that position came after the company appealed the decision. While the European Commission officially decides whether to approve a new medicine, it almost always follows the committee’s guidance. The final decision is expected to be made before the end of the year.

The drug, which won approval last year in the United States and is marketed Relyvrio, is designed to slow the progression of the fatal neurological condition. In its pivotal trial, patients who received the drug over 24 weeks scored about two points better on a 48-point scale of symptoms than those who got a placebo, indicating the drug slowed disease progression.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Apple Vision Pro: A first look at health apps on the new VR headset

WSS

Cassava Sciences’ Alzheimer’s clinical trials should be halted

SAMSHA loosens regulations on methadone treatment centers

A $475,000 price tag for a new cancer drug: crazy or meh?

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Readout LOUD podcast: Live from the 2023 STAT Summit

leisure time

leisure time

leisure time

Hollywood unions extend contract negotiations for actors

Covid misinformation case heads to Supreme Court

Dobbs anniversary: the lost opportunity of abortion as health care

STAT Summit: Meghan O’Rourke on making chronic illness visible

Hollywood unions extend contract negotiations for actors

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Medical leaders decry Supreme Court decision on affirmative action

Novo Nordisk to expand supply of Wegovy for U.S. patients

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Vertigo drug brings hope for rare neuron disorder, Niemann

entertainment

Merck, Daiichi strike cancer drug pact worth up to $22 billion

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Do digital therapeutics have a future in medicine?

STAT Readout: Friday, Oct. 20 biotech updates

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

SAMSHA loosens regulations on methadone treatment centers

focus

leisure time

hotspot

entertainment